This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Genentech: Avastin Breast Cancer Study Meets Goal

Genentech (DNA) and partner Roche said Tuesday that a second late-stage trial for blockbuster drug Avastin in combination with chemotherapy was successful in prolonging progression-free survival in certain breast cancer patients.

In the trial, dubbed AVADO, doses of Avastin at both15 mg per kg of docetaxel chemotherapy and 7.5 mg per kg of chemotherapy prolonged progression-free survival, or the amount of time patients have before their tumors start growing again, in breast cancer patients who hadn't been previously treated with chemotherapy. That met the primary goal of the trial.

Genentech didn't provide more specific data, but said it would be submitted for presentation at an upcoming medical meeting.

The news comes ahead of a key Food and Drug Administration decision on whether to approve Avastin for breast cancer. The drug currently is approved for colorectal and advanced non-small cell lung cancers.

In December, an FDA advisory panel voted 5 to 4 to recommend against approving Avastin in combination with paclitaxel chemotherapy for metastatic breast cancer. The panel's concern was based on the data available from a study in which the drug increased progression-free survival, but not overall survival, and added significant side effects. The agency is set to make a decision on the drug on February 23.

"We have shared the AVADO data with the FDA to assist the agency in assessing the risk and benefit of Avastin in this patient population," Genentech said in a press release Tuesday. "Genentech believes that the results of the AVADO study provide confirmation of Avastin's efficacy and safety in this patient population."

Bear Stearns analyst Mark Schoenebaum wrote in an email to investors that the AVADO trial wasn't designed to be accepted for FDA approval, but an ongoing RIBBON-1 trial was. He expects positive data from that study in the third quarter, noting that if Genentech receives an approvable letter pending more progression-free survival data he expects it will submit data from both the AVADO and RIBBON-1 studies by year end.

"We continue to believe that the risk/reward for DNA shares is highly favorable ahead of the Feb 23rd approval deadline, as most investors expect a significant delay," he said in the note. "However, in the off-chance that the FDA approves Avastin for breast cancer (~25% probability), upside could be substantial, in our opinion."

If the FDA indicates that overall survival data is indeed necessary, approval could be delayed substantially, Schoenebaum wrote, though he thinks this is scenario unlikely.

Shares of Genentech were gaining $1.58, or 2.3%, to $71.50 in after-hours trading Tuesday.

Check Out Our Best Services for Investors

Action Alerts PLUS

Jim Cramer and Stephanie Link reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

Jim Cramer's protégé, David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
Try it NOW
Try it NOW
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

Jim Cramer's protégé, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 17,416.85 +225.48 1.31%
S&P 500 2,021.25 +19.09 0.95%
NASDAQ 4,683.4070 +45.4130 0.98%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs